Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Inclusion Criteria: * Documented diagnosis of NDO, confirmed by urodynamics * Weight and height are within normal percentiles (3rd to 97th percentile) according to Centers for Disease Control and Prevention (CDC) growth charts * Subject's bowel function is being actively managed * Able to swallow the study medication in accordance to the protocol * Female subjects of childbearing potential and sexually active agree to use a reliable form of birth control for the duration of the study and for at least one month after ending study treatment. Sexually active male subjects agree to use a barrier method of birth control for the duration of the study and for at least one month after ending study treatment * Subject and subject's parent(s)/legal guardian are willing and able to comply with the study requirements and with the concomitant medication restrictions Exclusion Criteria: At screening: * Subject is breastfeeding or pregnant. Subjects of childbearing potential must have a negative serum pregnancy test * Subject with any of the following gastrointestinal (GI)conditions: partial or complete bowel obstruction, decreased motility (e.g., paralytic ileus) or at risk for gastric retention * Current fecal impaction or history of hospitalization for fecal impaction with enema in the past 2 years * History of QTc prolongation or risk of QT prolongation (e.g., hypokalemia, family history of Long QT Syndrome \[LQTS\]). QT interval greater than 470 ms at baseline * Any clinically sign…